Slide 1: Zur Rose Group
ZurRKose Group
Slide 2: FY Results 2021
FY Results 2021 Walter Oberhansli | Marcel Ziwica | Walter Hess 24 March 2022
Slide 3: Today's presenters
Today’s presenters Walter Oberhansli Founder, Group CEO Zur Rose Group Marcel Ziwica Group CFO FY Results 2021 Walter Hess Head Germany
Slide 4: Introduction
Introduction Strong strategic progress - eRx delay as lowlight All set for e-prescriptions with the new DocMorris healthcare app 1.3 million downloads New high for DocMorris brand recognition 71% aided awareness Steady revenue Vitalsana and New position of Strategic growth of apo-rot brands CTO emph
Slide 5: Summary FY 2021 Financial Results
Summary FY 2021 Financial Results
Slide 6: FY 2021 Financial Results
FY 2021 Financial Results in million CHF +14.8%1 +22.3%1 +19.4%1 +5.7% 2034.02 1761.7 FY 2020 Switzerland Germany Europe FY 2021 external revenue(3) external revenue(3) external revenue(3) Notes: 1 In local currencies | 2 Including eliminations of CHF 6.9 million | 3 Consolidated revenue of the Zur
Slide 7: Group B2C & Marketplace KPIs
Group B2C & Marketplace KPIs Active customers1 Repeat order rate2 Site visits3 in millions FY 2020 H1 2021 FY 2021 FY 2020 H1 2021 FY 2021 Basket size4 Order frequency5 in EUR Rx OTC 11.7 12.4 10.5 122 117 115 4.2 4.0 3.7 41 40 39 2.1 2.0 2.1 FY 2020 H1 2021 FY 2021 FY 2020 H1 2021 FY 2021 FY 2020 H
Slide 8: Income Statement
Zur Rose Group Income Statement FY 2021 Margin in % FY 2020 Margin in % in million CHF External revenue 2034.0 1761.7 Consolidated revenue 1726.5 1476.9 Gross profit adj. 263.0 15.2 250.9 17.0 Personnel expenses adj. (143.1) (8.3) (126.8) (8.6) Marketing expenses (118.8) (6.9) (60.6) (4.1) Distribut
Slide 9: Income Statement
Zur Rose Group Income Statement FY 2020 FY 2021 Adj. Adj. EBITDA EBITDA in million CHF (2.1%) eRx readiness (7.5%) & marketing (31.2) Increased growth expenses Accelerated Tech (34.2) development Rebranding & OTC France New (18.7) businesses (15.3) Other (13.4) (9.9) (6.1) (128.9)
Slide 10: Income Statement
Zur Rose Group Income Statement FY 2020 FY 2021 EBITDA adjustments Adj. EBITDA adjustments Adj. EBITDA EBITDA in million CHF in million CHF (5.3%) (2.1%) (8.3%) (7.5%) VAT Other1 accrual (31.2) M&A Integration 12.1 13.7 3.5 M&A Integration Other1 (78.4) 17.9 2.2 1.9 (128.9) (142.6) 9.6 Notes: 1 Main
Slide 11: Balance Sheet
Zur Rose Group Balance Sheet 31 Dec 2021 % 31 Dec 2020 % in million CHF Cash and cash equivalents 277.7 300.6 Receivables 166.5 145.4 Inventories 92.5 92.9 Property, plant & equipment 98.7 96.6 Intangible assets 595.4 604.5 Other assets 38.4 38.5 Total assets 1269.2 1278.5 Financial liabilities 83.8
Slide 12: Strategy Update
Strategy Update
Slide 13: Digital Health Ecosystem strategy confirmed
Strategy Update Digital Health Ecosystem strategy confirmed Digital Health Ecosystem Customers‘ preferred digital health destination . Operations Services Brands Best-in-class latte Platiorm Technology platform Profitable Creating added value for growth Patients, customers, partners, shareholders, e
Slide 14: Great talents added to our team
Strategy Update Great talents added to our team — Matthias Peuckert will join as Head Germany and CEO DocMorris in April 2022 — E-Commerce expert with 14 years of experience with Amazon — CEO of windeln.de from 2018-2022 — Besides technology and E-commerce also digital marketing, data & science and
Slide 15: Keep Best eRx Starting Position
Keep Best eRx Starting Position
Slide 16: eRx readiness criteria
eRx 1. 30’000 fully processed eRx 2. 99.9% availability of eRx infrastructure 3. Health insurers eRx ready & no retaxation 4. No severe errors 5. Physician information systems eRx ready 6. Pharmacy information systems eRx ready
Slide 17: eRx market opportunity
eRx 25% Rx online market OTC EUR 12.3bn3 10% Rx online market Rx EUR 4.9bn 1% Rx online market EUR 0.4bn Notes: 1 Sempora 2020 2 Kantar 2022 3 Assuming constant German Rx market size of EUR 49 bn
Slide 18: eRx vs non-Rx and pRx economics
eRx non-Rx pRx eRx Basket size Contribution margin after fulfillment costs Fulfillment / operations per order Gross margin Note: 1 As of 23 March 2022
Slide 19: Operational Leverage
Operational Leverage
Slide 20: Ensuring operational efficiency to capture the eRx opportunity
Operational Leverage Ensuring operational efficiency to fully capture the eRx opportunity — Management fully committed to reach EBITDA break-even in 2024 — Gross margin increase through category management, services and procurement — Improvement of marketing performance, reduction of operational cos
Slide 21: Go-Live of new distribution center on track
Operational Leverage Go-Live of new distribution center on track — Go live in Q2 2022 with low risk due to modular set up and extensive testing — Increased will lead to a yearly — Additional capacity of 15 million parcels per year more than doubles capacity in Heerlen Zur Rose Group
Slide 22: Growth Focus DocMorris
Growth Focus DocMorris
Slide 23: Growth Focus DocMorris: online channel market share
Growth Focus DocMorris Market share of online channel Size of non-Rx online channel in EURbn 2.5 2.6 2.2 1.9 2018 2019 2020 2021 Existing customer sales New customer sales Sales carry over rate 2019 2020 2021 2022 Source: 1 Insight Health 2022 non-Rx Sales excl. diagnostics in mail-order pharmacies
Slide 24: Focus DocMorris - double digit non-Rx growth
Growth Focus DocMorris Focus DocMorris — double digit non-Rx growth — Focus on double-digit non-Rx growth with core brand DocMorris — Priority 2022 on customers with Rx potential and higher CLVs to set the base for sustainable growth going forward — Reinforced marketing performance with strengthened
Slide 25: Growth Focus DocMorris
Growth Focus DocMorris Note: Example screenshot for illustration purposes
Slide 26: Summary: key priorities for 2022
Summary Our key priorities for 2022 Zur Rose Group FY Results 2021 26
Slide 27: Outlook
Outlook ‘Zur Rose Group FY Results 2021 27
Slide 28: Outlook: adj. EBITDA development
Outlook eRx potential adj. EBITDA in million CHF FY 2021 FY 2022 FY 2024 Structural synergies eRx Performance Readiness improvement incl. DC2 (75)-(95) Gross margin eRx DC2 improvement Readiness Marketing (128.9) reduction Gross margin improvement Note: Illustrative, not true to scale
Slide 29: Financial Outlook
Financial Outlook Financial Outlook We are confident that the German eRx market will ramp up in 2022 and this remains our core growth and profitability driver. As the timing is not yet confirmed we exclude any eRx impact from the outlook for 2022. Zur Rose Group FY Results 2021
Slide 30: Q&A
Q&A ‘Zur Rose Group FY Results 2021 30